Lymphatic Filariases, Scabies, Strongyloidiasis, Trachoma, Yaws
Conditions
Keywords
Neglected Tropical Diseases
Brief summary
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF. Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole community. Communities will be randomised to receive either treatment with IDA and Azithromycin on the same day or separately. Active monitoring for adverse events will be conducted and the frequency of adverse events compared between individuals receiving combined MDA or separate MDA.
Detailed description
Recent studies have shown that single-dose combination therapy with three antifilarial drugs (Ivermectin \[IVE\] + DEC + ALB) called IDA is superior to current regimens used in LF elimination and may help accelerate LF elimination. WHO guidelines have changed to recommend IDA in countries endemic for LF outside sub-Saharan Africa like Papua New Guinea. Additional benefits of IVE are its activity against scabies and Strongyloides. Treatment with IVE has shown to reduce the high prevalence of scabies in a village and in randomized control trials elsewhere in the Pacific. Of particular importance was the finding that IVE was highly effective against Strongyloides with a \>95% reduction in prevalence sustained for nine months. Increasingly, the desirability of linking LF programs with other public health initiatives also based on MDA is being appreciated. The existing programmatic infrastructure developed for LF campaign presents an attractive vehicle for a demonstration project of integration of MDAs against multiple Neglected Tropical Diseases (NTDs). The macrolide antibiotic azithromycin (AZI) has been demonstrated to be highly effective as MDA for yaws control and AZI is a highly effective and well-tolerated antibiotic treatment for trachoma that is able to clear ocular infection with a single oral dose and is well tolerated. Currently LF/STH/Scabies/strongyloides and yaws/trachoma are treated separately. Integration of these existing MDA programs has the potential to be highly cost-effective as a population health intervention. Integration includes both the safe co-administration of medicines and operational planning, and it is currently advocated by WHO.
Interventions
DRUGAlbendazole on Day 1
Albendazole 400 mg oral tablet Single Dose Treatment on D1
DRUGIvermectin on Day 1
Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
DRUGDiethylcarbamazine on day 1
Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
DRUGAzithromycin on Day 1
Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
DRUGAzithromycin on Day 8
Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
Sponsors
London School of Hygiene and Tropical Medicine
Lihir Medical Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Able to give consent
Exclusion criteria
* Unable to give consent. * Less than 5 years of age (not eligible for ivermectin)\*\* * Pregnant women (azithromycin only, not eligible for albendazole and ivermectin) * Lactating women (Only administered azithromycin and albendazole, not eligible for ivermectin)\*\* * History of allergies to the drugs being studied * Residents who cannot swallow tablets Note that patients that are not eligible for a specific drug will receive all other treatments and will be followed up through the same procedure as the other participants drug therapy to try to track any AEs attributed to specific drug combinations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self Reported Adverse Event | 7 Days | The incidence of self-reported adverse events following MDA. We will collect data on the presence of common symptoms/signs prior to drug administration. All patients will be reviewed 24-48 hours after treatment and asked to report adverse events. We will calculate the proportion of newly occurring adverse events following treatment and calculate the whether the proportion of patients experiencing an adverse event differs between study arms. |
Countries
Papua New Guinea
Outcome results
None listed